Jenna C Podjasek1, Joseph H Butterfield. 1. Division of Allergic Diseases, and the Mayo Clinic Program for Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, MN 55905, USA. podjasek.jenna@mayo.edu
Abstract
BACKGROUND: Information in the literature regarding causes of mortality in patients with hypereosinophilic syndrome (HES) is limited. METHODS: This was a retrospective review of the morbidities and causes of death in HES patients at Mayo Clinic. RESULTS: Overall, out of the 247 diagnosed HES patients, 23 died during the 19 years that this review encompassed. The cause of death was identified in 15 patients (65%): cardiac dysfunction in 5 (33%), infection in 3 (20%), unrelated malignancy in 3 (20%), thromboembolic phenomena in 2 (13%), and vascular disease in 2 (13%). CONCLUSION: Targeted monitoring of the at-risk end organs, combined with early treatment, may have the ability to improve survival and reduce morbidity in HES patients.
BACKGROUND: Information in the literature regarding causes of mortality in patients with hypereosinophilic syndrome (HES) is limited. METHODS: This was a retrospective review of the morbidities and causes of death in HESpatients at Mayo Clinic. RESULTS: Overall, out of the 247 diagnosed HESpatients, 23 died during the 19 years that this review encompassed. The cause of death was identified in 15 patients (65%): cardiac dysfunction in 5 (33%), infection in 3 (20%), unrelated malignancy in 3 (20%), thromboembolic phenomena in 2 (13%), and vascular disease in 2 (13%). CONCLUSION: Targeted monitoring of the at-risk end organs, combined with early treatment, may have the ability to improve survival and reduce morbidity in HESpatients.